Bifidobacterium septicaemia in an extremely low-birthweight infant under probiotic therapy

ADC Fetal & Neonatal Edition, 05/01/2012

Studies on probiotics for prevention of necrotising enterocolitis (NEC) show a risk reduction across all studies from 6.6% (165/2493) in the untreated to 2.5% (62/2433) in the treated patients.1 However, modest limitations in all studies, for example, uncharacteristically high–baseline rate of NEC2– warrant cautious risk–benefit consideration.

Print Article Summary Cat 2 CME Report